Related Experiment Video
Updated: Jun 12, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
9.4K
Pharmacogenomics Tools for Precision Public Health and Lessons for Low- and Middle-Income Countries: A Scoping
Angélica Borbón1, Juan Carlos Briceño2, Augusto Valderrama-Aguirre3
1Technological Innovation Management, University of the Andes, Bogotá, Colombia.
Pharmacogenomics and Personalized Medicine
|February 4, 2025
Summary
Pharmacogenomic tools are advancing rapidly, primarily developed in high-income nations. This study highlights the urgent need for increased investment in low- and middle-income countries to ensure equitable access to precision public health strategies.
Area of Science:
- Genomics and Pharmacology
- Precision Public Health
- Health Technology Development
Background:
- Pharmacogenomics (PGx) integrates genomics and pharmacology for personalized medicine.
- Precision Public Health (PPH) uses population-level data for public health strategies.
- Technological tools are crucial for advancing both PGx and PPH.
Purpose of the Study:
- To conduct a scoping review of pharmacogenomic technological tools.
- To examine the evolution and geographical distribution of these tools.
- To identify gaps and needs, particularly in low- and middle-income countries (LMICs).
Main Methods:
- Scoping review conducted according to ScPRISMA guidelines.
- Literature search in PubMed, Web of Science, and Embase until January 2024.
- Selection and analysis of 40 relevant documents.
Main Results:
- Pharmacogenomic tools show continuous evolution and development.
- Technological tool development is predominantly led by high-income countries (US, Canada, China, Europe).
- International collaboration is key to tool maintenance and expansion.
- There is scarce development of PPH technological tools in LMICs.
Conclusions:
- Significant disparities exist in the development of pharmacogenomic tools globally.
- Increased investment in genomic research infrastructure and capacity building in LMICs is essential.
- Global accessibility to PPH advances requires addressing these developmental gaps.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...